Expand ACAD Menu
ACAD MENU

ACAD Latest Press Releases

-- October 1, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD PRNewswire 10:03 AM

-- September 29, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD Globe Newswire 5:29 PM
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 Business Wire 8:06 AM

-- September 24, 2026 --

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis (ADP) Business Wire 7:00 AM

-- August 24, 2026 --

European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union Business Wire 3:01 AM

-- August 4, 2026 --

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results Business Wire 4:05 PM

-- July 30, 2026 --

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference Business Wire 5:57 PM

-- July 20, 2026 --

Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis Business Wire 9:05 AM

-- July 15, 2026 --

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 Business Wire 4:05 PM

-- July 6, 2026 --

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer Business Wire 9:04 AM

-- June 26, 2026 --

DAYBU (trofinetide) Recommended for Approval in the European Union by CHMP Business Wire 6:49 AM
Market Data Delayed 15 Minutes